Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05615623 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
This record was last updated April 21, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Record History
MinorTrial status: Recruiting to Active, Not RecruitingPrimary completion date: Jan 2026 to Jun 2026 · Completion date: Jul 2026 to Oct 2026 · Site details revisedv6Show 3 more changesShow less
Primary completion date: Jan 2026 to Jun 2026
Completion date: Jul 2026 to Oct 2026
Site details revised
NotableEnrollment target: 3 to 10Primary completion date: Jan 4, 2025 to Jan 2026 · Completion date: Jul 4, 2025 to Jul 2026v5Show 2 more changesShow less
Primary completion date: Jan 4, 2025 to Jan 2026
Completion date: Jul 4, 2025 to Jul 2026
MinorRe-verified, no change to tracked fieldsv4
MinorPrimary completion date: Nov 1, 2024 to Jan 4, 2025Completion date: May 1, 2025 to Jul 4, 2025 · Start date changed from estimate of Dec 10, 2022 to Jan 4, 2023v3Show 2 more changesShow less
Completion date: May 1, 2025 to Jul 4, 2025
Start date changed from estimate of Dec 10, 2022 to Jan 4, 2023
NotableStart date: Nov 1, 2022 to Dec 10, 2022v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients